Lymphoma
Our latest articles

Observational studies: some examples in hematology.
Clinical trials include interventional trials and observational trials. Observational trials do not require additional actions compared to the patient’s routine treatment.

Explanations on non-Hodgkin lymphomas.
Non-Hodgkin lymphomas (NHL) are divided into two main types: T-cell lymphomas and B-cell lymphomas. For T-cell lymphomas, the tumor originates from mature T cells, unlike most NHLs, which are derived from mature B cells.

Focus on mantle cell lymphoma
Mantle cell lymphomas are B-cell lymphomas. They start in cells in the outer periphery (mantle zone) of the lymph nodes.

Better understand Hodgkin lymphoma.
There are several types of lymphomas, including Hodgkin lymphoma, which accounts for about 10% of lymphomas. Hodgkin lymphoma affects the lymphatic system, which consists of all the white blood cells that circulate in the blood. More particularly, it corresponds to an abundant proliferation of abnormal B lymphocytes.
Frequently asked questions
What is indolent B-cell lymphoma?
Indolent non-Hodgkin lymphoma (NHL) tends to develop very slowly and patients usually only show symptoms at an advanced stage of the disease.
In particular, we find:
- Follicular lymphoma
- Marginal zone lymphoma
- Nodular lymphocyte-predominant B lymphoma
- Etc...
A complete list can be found on the platform.
What is an autograft?
An autograft, also known as an autologous stem cell transplant, is a procedure in which hematopoietic stem cells are taken from the patient himself and reinjected after prior treatment. Unlike allograft, which uses stem cells from a compatible donor, autotransplantation uses the patient’s own stem cells. An autograft is used in the treatment of certain types of lymphoma, in order to allow the administration of higher doses of chemotherapy or radiation therapy than would be possible with conventional treatments.
What is immunotherapy for lymphomas?
Immunotherapy is a treatment that aims to stimulate the body’s immune defenses against cancer cells. Its effectiveness has been demonstrated in a large number of cancers, even if its tolerance is marked by a specific toxicity profile linked to the reactivation of the immune system.
Examples include checkpoint inhibitors (nivolumab, pembrolizumab) and CAR-T therapy, where the patient’s T cells are genetically modified to better fight cancer.
Gynaecological cancer
Pancreatic cancer
Paediatrics
Kidney cancer
Leukemia